Salivary diagnostics and its implementation in diagnosis of COVID19

Abstract

The coronavirus disease (COVID-19), epidemic started in Wuhan, caused by a novel coronavirus (SARS-CoV-2), has become a major public challenge around the world. Here, saliva diagnostic testing for COVID-19 is essential to controlling the global pandemic. The use of saliva has various advantages compared to collection of Nasopharyngeal swabs. The close contacts involved in swab collection have a risk to healthcare workers, and collection of saliva may reduce this risk. Presently, rapid testing is enchanting with the help of nasopharyngeal, oropharyngeal swab, bronchoalveolar lavage, sputum, urine, and blood. Saliva is demonstrating to be a capable non-invasive sample variety for the diagnosis of COVID-19, thus helping to detector the infection and prevent it from further spreading by prompt isolation. The saliva biomarkers have a potential to be an vital guide in COVID-19 diagnosis, making possible the development of sampling procedures. Salivary biomarkers connected with the improvement and evolution of COVID-19 could allow a well distinction among asymptomatic, mild, moderate or advanced disease.